INFOPACK

FEBRUARY 2022

Emerging Treatments in Schizophrenia

Christoph U. Correll, MD; Anissa Abi-Dargham, MD; and Oliver Howes, MRCPsych, PhD

CONTENTS

FACULTY

Christoph U. Correll, MD, Chair
Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York; and Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany

Anissa Abi-Dargham, MD
Department of Psychiatry, Renaissance School of Medicine, Stony Brook University, New York

Oliver Howes, MRCPsych, PhD
Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK

FACULTY DISCLOSURE

REVIEW PROCESS

The faculty for this INFOPACK discussed the content in a series of peer-review planning teleconferences, the chair and faculty reviewed the INFOPACK for accuracy, and a member of the Journal Editorial Board who is without conflict of interest reviewed the INFOPACK to determine whether the material is evidence-based and objective.

ACKNOWLEDGMENT

Emerging Treatments in Schizophrenia

ABSTRACT

Although antipsychotics have been available for almost 70 years and greatly improved outcomes for individuals with schizophrenia, all currently available options derive their efficacy from blockade of dopaminergic receptors. However, this mechanism of action leaves many symptoms unresolved and is associated with a significant side effect burden. The mechanisms underlying schizophrenia, which were initially thought to be related to excessive presynaptic dopamine in specific areas of the brain, are now understood to be much more complex and involve structural and molecular changes throughout brain circuits. Consequently, drug discovery efforts have sought new targets in the search for safer and more effective medications that can improve symptoms of schizophrenia and psychosis, including trace amine–associated receptors (TAARs), muscarinic receptors, and serotonergic receptors. Positive phase 2 trial results indicating efficacy and safety of the TAAR1 agonist ulotaront (SEP-363856) and of the muscarinic M1/M4 agonist KarXT (xanomeline plus trospium) for total, positive, and negative symptoms in patients with acute exacerbation of schizophrenia, and of the serotonin 5-HT2A agonist/antagonist pimavanserin in patients with schizophrenia and predominant negative symptoms for negative symptom control are encouraging. Taken together, these data indicate in the context of ongoing phase 3 trial programs that patients with schizophrenia may soon have access to the first non–D2 blocking medication, which could drastically change the treatment landscape and improve outcomes for many of the individuals with schizophrenia who do not fully respond to or cannot tolerate currently available antipsychotic agents that currently all act via postsynaptic dopamine D2 receptor blockade.

In the April 16, 2020, issue of *The New England Journal of Medicine,*[1] Koblan and colleagues published their findings from a phase 2 clinical trial of ulotaront (SEP-363856) in adults experiencing an acute exacerbation of schizophrenia. This trial found ulotaront to be significantly more effective than placebo for reducing Positive and Negative Syndrome Scale (PANSS) scores. This study has been met with great interest because, unlike all other available antipsychotic agents, ulotaront does not act on dopamine D2 receptors. This INFOPACK will begin with a summary of the trial conducted by Koblan et al, followed by an analysis by Drs Anissa Abi-Dargham, Oliver Howes, and Christoph U. Correll in which they put these data into the context of available drugs to treat psychosis, brain circuits thought to be involved in psychosis, and agents in phase 3 trial programs that aim to ameliorate psychotic symptoms without directly blocking postsynaptic dopamine receptors.

SUMMARY

A Promising New Treatment Target: Overview of a Randomized Controlled Trial of Ulotaront (SEP-363856) for Acute Exacerbation of Schizophrenia

—————— **Full article online from** *N Engl J Med* 2020;382(16):1497–1506 ——

Although several new antipsychotics have become available in the 7 decades since the introduction of chlorpromazine, all of these treatments have relied primarily on the same mechanism—blockade of postsynaptic dopamine D2 receptors. Because of the complex and heterogeneous nature of schizophrenia, discovery of new therapeutic targets has proven to be very difficult. Using an in vivo phenotypic approach, investigators were able to identify a new compound that exhibited behavioral effects consistent with an antipsychotic effect. This compound, SEP-363856 (since named *ulotaront* by the WHO classification system), has agonist activity at trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A [serotonin]) receptors[2] but with absence of D2 and 5-HT2A receptor blockade.[2] Following is an overview of the phase 2 trial of ulotaront,[1] which was originally published in *The New England Journal of Medicine.*

Trial methods. The trial was conducted from December 2016 through July 2018 across 34 sites in Eastern Europe and North America. The trial design is summarized in **Figure 1**. The active treatment phase was preceded by a screening and washout period of up to 14 days, during which all psychotropic medications were discontinued. Patients were then randomly assigned in a 1:1 ratio to receive either placebo or a flexible dose of ulotaront once daily at bedtime. No one involved in any aspect of the trial was aware of the treatment assignments. The initial dose of ulotaront was 50 mg with an option to increase to 75 mg on or after day 4. The dose could be reduced to 50 mg at any point if tolerability issues arose. The trial lasted for 4 weeks.

Results. The trial began with 245 enrolled patients—120 in the active treatment group and 125 in the placebo group. A total of 52 patients discontinued treatment, and they were split evenly between the active treatment and placebo arms. Reasons for treatment discontinuation are listed in **Table 1**. The primary efficacy measure was change from baseline in total PANSS score. Compared with patients receiving placebo, those receiving ulotaront experienced significantly greater reduction in total PANSS scores (–17.2 vs –9.7; *P* = .001). Patients in the ulotaront group also showed greater improvements in all secondary efficacy measures. The incidence

Figure 1. Trial Design[a]

Patients	Treatments	Endpoints
• Aged 18–40 y • Met *DSM-5* criteria for schizophrenia for at least 6 months • Experiencing an acute psychotic episode • CGI-S ≥ 4 • PANSS ≥ 80 • Previous hospitalizations for acute episodes ≤ 3 • No depot neuroleptic treatment within previous 30 days	Randomly assigned to either a flexible dose of ulotaront (SEP-363856) (50 mg or 75 mg) or placebo, taken daily at bedtime	• Primary: Change in total PANSS from baseline to week 4 • Secondary: Change from baseline in CGI-S, BNSS, MADRS

[a]Data from Koblan et al.[1]

Abbreviations: BNSS = Brief Negative Symptom Scale, CGI-S = Clinical Global Impressions Severity scale, MADRS = Montgomery-Asberg Depression Rating Scale, PANSS = Positive and Negative Syndrome Scale.

Table 1. Reasons for Treatment Discontinuation From the 4-Week Trial[a]

	Ulotaront (n)	Placebo (n)
Lack of efficacy	5	4
Adverse effects	10	8
Withdrew consent	9	14
Other	2	0

[a]Data from Koblan et al.[1]

Figure 2. Change from Baseline in Total PANSS Score in Patients Receiving Ulotaront (SEP-363856) or Placebo at 4-Week and 26-Week Endpoints

[a]Data from Koblan et al.[1]

[b]Data from Correll et al.[3] Over 80% of the patients who received ulotaront or placebo in the 4-week study chose to continue to the extension study where they received ulotaront, open label and flexible dose with no placebo arm, for 26 weeks.

Abbreviation: PANSS = Positive and Negative Syndrome Scale.

opted to enter a 26-week, open-label, extension study. They received flexible doses of ulotaront of 25 mg, 50 mg, or 75 mg per day. At endpoint, the total PANSS score of patients who had received ulotaront in the initial trial and who were then treated open label for another 26 weeks had been reduced by an additional average of 17.1 points in addition to the acute trial improvements (**Figure 2**[1,3]). The patients who had received placebo during the 4-week trial and then switched to ulotaront for the extension study exhibited a mean reduction in total PANSS score of 27.9. This combined group's cumulative change in total PANSS score from study entry to extension study endpoint was −37.6. Approximately 9% of patients experienced serious adverse events related to mental health, including schizophrenia exacerbations, psychosis, depression, and suicidal ideation. At the 26-week endpoint, with all patients taking ulotaront, the pooled weight change was −0.3 kg, and lipid measures showed decreases or no change.[3] Additional adverse effects reported were generally mild, with headache and insomnia being most common.

of side effects was comparable between the ulotaront and placebo groups, with the most common being somnolence, agitation, and nausea. Patients taking ulotaront gained an average of 0.3 kg in body weight, while those taking placebo lost an average of 0.1 kg. Total and low-density lipoprotein (LDL)–cholesterol levels decreased in patients taking ulotaront (no change in the placebo group). No other changes in metabolic measures were observed. The incidence of extrapyramidal symptoms was comparable in both groups.

Extension study. At the conclusion of the 4-week trial, 157 patients

Conclusions

In this phase 2 acute, double-blind, placebo-controlled trial and open-label extension study, treatment with ulotaront was associated with significant improvements in total PANSS score compared with placebo and was generally well tolerated. Ulotaront appears to be a promising new treatment, but larger trials are needed.

COMMENTARY

The Pathophysiology of Schizophrenia: A Brief Overview

Anissa Abi-Dargham, MD

Schizophrenia is a chronic disorder in which symptoms typically emerge in late adolescence or early adulthood. For most patients, these symptoms will progress through several clinical stages of worsening severity (**Figure 3**),[4] and they occur in clusters across multiple functional domains. These symptom clusters, which have been observed since schizophrenia was first identified as a distinct disorder, include deficits and dysfunction in perception, cognition, mood, movement, behavior, and reward.[4] Although clinical symptoms typically do not emerge until adolescence or early adulthood, decades of investigation have shown that they stem from widespread brain alterations that begin very early in life. Schizophrenia is thought of as a global brain disease, and a greater knowledge of the abnormalities that occur in different systems will likely lead to more effective, targeted treatments.

—— View video online ——

Neurodevelopmental Changes

Evidence indicates that environmental and genetic factors may affect brain development in utero, conferring vulnerability to the development of schizophrenia. These factors alter the brain's developmental trajectory leading to abnormalities in different circuits and transmitter systems.[4] Typically, synapse proliferation and migration occur from gestation through the first year of life, followed by a period of synaptic refinement and myelination lasting until early adulthood.[5] Excitatory synapses are pruned, while inhibitory synapses proliferate and develop connections, resulting in an intricate balance of excitation and inhibition. In schizophrenia, excessive pruning of excitatory synapses and a deficient development of inhibitory synapses are thought to result in an imbalance of excitation and inhibition. This imbalance has been a major focus of research in schizophrenia.

Imaging studies have provided evidence that schizophrenia is associated with structural changes in both gray and white matter. A meta-analysis of 27 magnetic resonance imaging (MRI) studies detected widespread gray matter decreases in the hippocampus, the insula, the anterior cingulate, various regions of the frontal cortex, the basal ganglia, and the thalamus.[6] These gray matter decreases may be the result of alterations at the cellular level. Postmortem studies have revealed abnormalities in circuitry in the prefrontal cortex (PFC) that may account for decreases in brain volume.[7] Patients with schizophrenia have been found to have decreases in somal size and dendritic spine density of pyramidal cells in the PFC. Furthermore, reductions in the enzyme that synthesizes GABA (γ-aminobutyric acid), as well as decreases in the GABA transporter levels, have been observed; these may contribute to decreases in gray matter volume and may lead to the imbalance of GABAergic and glutamatergic transmission that is needed for optimal cognitive function. White matter changes in schizophrenia have been investigated using diffusion tensor imaging, revealing abnormalities in frontotemporal white matter connectivity between certain cortical regions including the frontal, temporal, and genu of the corpus callosum regions.[8] White matter tract abnormalities are associated with severity of clinical symptoms.

MRI has revealed abnormalities associated with schizophrenia in additional parts of the brain. An imaging study[9] by Schobel and colleagues examined cerebral blood volume (CBV) in patients with schizophrenia, patients at high risk for developing schizophrenia, and healthy controls. Enhanced CBV, which indicates areas of neuronal overactivity, was found in the CA1 subfield of the hippocampus in both the schizophrenia and high-risk groups. CBV, therefore, could be useful as a biomarker to identify patients who will progress to schizophrenia, although a replication of this finding has not yet been reported. The auditory cortex is also overactive in schizophrenia. A

Figure 3. Stages of Illness in Schizophrenia[a]

[Healthy — Worsening-Severity of Signs and Symptoms]
Premorbid; Prodromal Onset/Progression; Deterioration; Chronic/Residual
Gestation/Birth, 10, Puberty, 20, 30, 40, 50 — Age (y)

[a]Reprinted with permission from Lieberman et al.[4]

functional (f)MRI study[10] found that the auditory cortex in patients with schizophrenia is hyperactive during silence, and this hyperactivity is associated with the severity of auditory hallucinations.

Neurochemical Changes

Advances in imaging technology have allowed investigation of the neural circuitry underlying schizophrenia. Normal brain function requires information processing through interactions among different neural networks.[11] In particular, the basal ganglia-thalamocortical (BGTC) network controls the flow of information from the cerebral cortex, into striatum, pallidum, and thalamus, feeding back into the cortex.[12] These BGTC loops receive inputs from dopaminergic projections arising from the midbrain, including ventral tegmental area and substantia nigra; they have a major influence in organizing behavior across different functional domains. (See Figure 6.)

Within the BGTC network, output from the striatum consists in medium spiny GABAergic projection neurons. These neurons are distinguished in 2 pathways according to whether they have D1 or D2 receptors. The D1 pathway is considered the "go" pathway, or direct pathway, and it facilitates communication between the thalamus and the cortex. The D2 pathway is the "no-go" pathway, or indirect pathway, and it inhibits thalamocortical communication. The balance between "go" and "no-go" pathways is involved in determining approach and avoidance behavior across the different domains of function[13] subserved by these BGTC loops. This important functional network is thought to be disrupted in schizophrenia, which leads to cognitive and behavioral symptoms. Although a number of neurotransmitters are involved in the processing of information through neural networks, one main dysfunction is thought to stem from dopaminergic abnormalities.[12]

Dopamine. Dopamine is critical for understanding schizophrenia and has been a major focus of research into the pathophysiology of the illness and treatment development. The earliest

Figure 4. Evolution of the Dopamine Hypothesis of Schizophrenia[a]

Schizophrenia is caused by excessive dopamine neurotransmission.

Positive symptoms are caused by hyperdopaminergia in the striatum; negative symptoms are caused by hypodopaminergia in the prefrontal cortex.

Dopamine dysregulation stems from interaction of genetic and environmental risk factors, originates at the presynaptic level, is associated with psychosis rather than schizophrenia, and leads to abnormal processing of stimuli.

[a]Based on Howes and Kapur.[14]

evidence of dopamine's involvement in schizophrenia was based on clinical observations, such as the observation that antipsychotic drugs that bind to D2 receptors were effective at reducing positive symptoms.[12] Similarly, dopamine agonists were found to induce or worsen psychosis. These observations led to the hypothesis, which has evolved over time, that psychotic symptoms stem from an excess of dopamine in the striatum (**Figure 4**).[14]

Once imaging technology was available to investigate dopaminergic activity in the striatum, studies were able to detect a number of schizophrenia-related changes to the striatal dopamine synaptic machinery, namely elevations in presynaptic dopamine synthesis capacity, dopamine release, and dopamine D2 receptor density.[14] More specifically, dopamine hyperactivity is most pronounced in the associative regions of the striatum and is evident beginning in the prodromal stage of schizophrenia.[15,16] This increase in dopamine in the associative striatum is thought to be the basis of positive symptoms. In the ventral striatum, low levels of dopamine relate to negative symptoms, while in the associative striatum, high levels of dopamine relate to psychotic symptoms.[17]

The manner in which striatal dopaminergic dysfunction manifests as

positive and negative symptoms is related to dopamine's role in learning through salience processing and reward prediction.[17] Research shows that the firing pattern of midbrain dopamine neurons tracks the mismatch between expectations of rewards and the experience of rewards. If a reward is the same as what was expected, dopamine firing remains stable, but if the reward is better than expected, dopamine firing increases, and if the reward is worse than expected, dopamine firing is diminished. Both of these processes are important to reinforce learning and guide future behavior.[18]

In patients with schizophrenia, dopamine cells may fire unpredictably in response to stimuli and rewards.[19] If dopamine cells fire in response to insignificant stimuli, thus investing those with unwarranted meaning, this may form the basis for delusional thinking. Conversely, individuals with schizophrenia show a blunted dopaminergic response to reward anticipation, which may correspond to negative symptoms.[17]

Investigation into dopamine dysfunction in schizophrenia progressed from the original hypothesis that focused on striatal dopamine to a more complex framework, which acknowledged that dopamine dysfunction was spread throughout different regions of the brain.[7] Five dopaminergic pathways (includes 2 nigrostriatal pathways) have been identified that are involved in the symptoms and pathology of schizophrenia (**Figure 5**).[20] All 5 of these pathways begin in the midbrain, in either the ventral tegmental area or the substantia nigra. From the midbrain, dopamine projects to regions of the cortex, thalamus, and striatum. This functional connectivity is integral to the BGTC functional network. In schizophrenia, abnormal dopamine transmission in the striatum may relate to abnormal functional connectivity of the striatal substructures to the rest of the brain.[12]

Dopaminergic dysfunction in cortical regions is now understood to be a central part of the pathophysiology of schizophrenia. Dopaminergic receptors in the PFC maintain a balance of

Figure 5. Disruption of Dopamine Pathways Leads to Predictable Effects[a]

1. **Mesocortical Pathway**
   • **Negative symptoms**
   • **Cognitive impairment**
   • **Depression**

2. **Mesolimbic Pathway "Limbic Striatum"**
   • **Negative symptoms**

3. **Nigrostriatal Pathway 1 "Associative Striatum"**
   • **Psychosis**

4. **Nigrostriatal Pathway 2 "Sensorimotor Striatum"**
   • **Dystonia**
   • **Akinesia**
   • **Rigidity**
   • **Tremor**
   • **Dyskinesia**

5. **Tuberoinfundibular Hypothalamic Pathway**
   • **Prolactin elevation**
   • **Amenorrhea**
   • **Galactorrhea**
   • **Sexual dysfunction**

[a]The predominant hypothesis regarding the pathophysiology of schizophrenia is that it is associated with impaired dopamine neurotransmission. Five main dopaminergic pathways have been described:

1. The **mesocortical pathway** originates from the ventral tegmental area in the midbrain and innervates areas of the frontal cortex. It has been implicated in aspects of learning and memory and the negative symptoms of schizophrenia.

2. The **mesolimbic pathway** originates from the ventral tegmental area in the midbrain and innervates the ventral striatum, olfactory tubercle, and parts of the limbic system. It has been implicated in some of the negative symtpoms of schizophrenia.

3. The **nigrostriatal pathway 1** originates in the substantia nigra and innervates the associative striatum. It is involved in the control of emotions and assignment of salience to stimuli.

4. The **nigrostriatal pathway 2** originates in the substantia nigra and innervates the sensorimotor striatum. It is involved in control of movement, eg, tardive dyskinesia, and other extrapyramidal symptoms.

5. The **tuberoinfundibular hypothalamic pathway** projects from the hypothalamus to the anterior pituitary gland. It controls prolactin secretion.

Overactivity of the nigrostriatal pathway 1 (associative striatum) has been implicated in development of positive symptoms of schizophrenia. The negative symptoms of schizophrenia have been associated with underactivity in parts of the mesolimbic and mesocortical pathways. Similarly, underactivity in parts of the mesocortical pathways have been associated with cogntive dysfunction in schizophrenia.

According to this conceptualization, the overall goal of treatment in patients with schizophrenia is to reduce the activity of hyperactive pathways mediating psychosis and to increase the activity of hypoactive pathways that seem to mediate negative and cognitive symptoms, while simultaneously preserving the activity of those pathways that regulate motor movement and prolactin secretion.

excitation/inhibition by modulating glutamate neurotransmission and GABAergic interneuron function.[21] This microcircuitry matures during adolescence, achieving optimal stimulation of the pyramidal cells and the GABAergic interneurons by dopamine receptors and resulting in more efficient and fine-tuned cortical activity. In schizophrenia, this maturation does not occur, leading to functional and behavioral deficits.[21]

Cortical dopamine release is thought to be deficient in patients with schizophrenia. Slifstein and colleagues[22] conducted an imaging study to observe amphetamine-induced dopamine release in the dorsolateral PFC of

20 patients with schizophrenia and 21 healthy controls. Compared with controls, individuals with schizophrenia showed reduced dopamine release not only in the dorsolateral prefrontal cortex (DLPFC), but also in most cortical and extrastriatal regions. Furthermore, the diminished dopamine release capacity in the DLPFC of patients was correlated with poor performance on a working memory task, as reported by Cassidy and colleagues.[23]

In summary, a great deal of evidence supports the involvement of dopaminergic dysfunction in the pathophysiology of schizophrenia. Excess dopamine has been observed

in the striatum, but deficit of dopamine has been observed everywhere else, in particular, the regions important for executive function, working memory, and social cognition.

Glutamate. Dysfunction of the glutamatergic system is also thought to be involved in the pathophysiology of schizophrenia. Glutamate is the main excitatory neurotransmitter in the central nervous system, and glutamatergic neurons are found throughout the brain. Numerous types of glutamate receptors exist, classified as either ionotropic or metabotropic. Ionotropic receptors can be further classified as either *N*-methyl-D-aspartate (NMDA) receptors or non-NMDA receptors. Ionotropic receptors affect the firing pattern of dopaminergic neurons in the midbrain.[24] Glutamatergic dysfunction was first hypothesized to contribute to schizophrenia after it was discovered that the administration of NMDA antagonists led rodents and non-human primates to exhibit behavior reminiscent of schizophrenia-like symptoms in humans.[25] In humans, healthy controls who have been administered phencyclidine or ketamine, both of which are NMDA receptor antagonists, have been found to exhibit behaviors similar to the positive, negative, and cognitive symptoms of schizophrenia.

NMDA receptor antagonists such as ketamine inhibit NMDA receptors on GABA interneurons, leading to reductions in extracellular GABA levels and increases in extracellular glutamate levels, resulting in increased cortical activity. An fMRI study[26] was conducted in which healthy volunteers were given an infusion of ketamine in order to investigate changes in functional brain connectivity and the manner in which these changes might relate to symptoms. Global functional hyperconnectivity was observed after 45 minutes of continuous administration. Region-specific changes in global brain connectivity were identified that predicted positive and negative symptoms, and these correspond to the abnormalities in functional connectivity that have been observed in schizophrenia.

Studies have used proton magnetic resonance spectroscopy (^{1}H-MRS) to

examine glutamate in different brain regions in schizophrenia, particularly the frontal cortex.[27] A meta-analysis was conducted of ^{1}H-MRS imaging studies that compared glutamate and glutamine concentrations in the brains of people with schizophrenia and healthy controls. Glutamine is a metabolite of glutamate and is considered an indicator of glutamate neurotransmission.[25] Compared with healthy controls, patients with schizophrenia were found to have higher concentrations of glutamine and lower concentrations of glutamate in the frontal region. These levels of both glutamate and glutamine were found to decrease with age. Thus, abnormalities in the glutamatergic system change as the illness progresses. Early in the illness, increased glutamate in the frontal cortex is associated with severity of positive symptoms, but with time and exposure to medications, glutamate decreases, as do positive symptoms.

Additional neurotransmitter dysfunctions. The pathophysiology of schizophrenia is increasingly understood as stemming from dysfunction in multiple interconnected neurotransmission circuits. Abnormalities in the cholinergic system that have been observed in schizophrenia include a reduced number of cholinergic interneurons in the striatum, reduced numbers of M1 and M4 receptors in the caudate and putamen, and reduced muscarinic receptor availability in the cortex and basal ganglia.[28] Cholinergic projections from the brainstem extend to the midbrain where they stimulate

Schizophrenia is a multifactorial disease, involving genetic and environmental factors, as well as abnormalities in brain development, circuitry, and synchrony. These abnormalities occur on structural, functional, and molecular levels and have widespread effects on cognitive functioning.

—Dr Abi-Dargham

dopamine neurons in the substantia nigra and ventral tegmental area. This leads to dopamine release along the mesolimbic pathway and increased dopamine in the striatum.[28] The cholinergic system also interacts with the glutamatergic and GABAergic systems, thus suggesting that any dysfunction in acetylcholine neurotransmission could disrupt the balance of excitation and inhibition maintained by glutamate and GABA signaling.[29]

Trace amine–associated receptors were only discovered in 2001, and although much has been discovered regarding their structure, location, and function, a great deal remains unknown.[30] TAARs are distributed throughout the body, and they can be activated by not only trace amines, but also monoamines such as dopamine or serotonin, meaning they have the potential to modulate these neurotransmitters. A number of TAARs have been identified, but TAAR1 has been studied most extensively and is the most widespread TAAR in the brain. They are G-protein–coupled receptors

and are mostly located intracellularly, but they can transfer to the plasma membrane after creating a heterodimer with another receptor.[31] Of particular relevance to schizophrenia, TAAR1 has the ability to undergo heterodimerization with plasma membrane D2 receptors leading to internalization of both receptors, thereby reducing dopamine expression,[32] and is also positioned to modulate serotonergic and glutamatergic signaling.[33] Genetic variations in TAAR1 have been observed in individuals with schizophrenia that may contribute to dopaminergic dysfunction.[34]

Conclusions

Schizophrenia is a complex disorder that is still not fully understood. Decades of research have revealed neurodevelopmental, structural, functional, and molecular abnormalities that all contribute to positive, negative, and cognitive symptoms and that may provide targets for future treatments.

Test Your Knowledge 1 ?

Schizophrenia may involve:

A. Dopaminergic excess in the associative striatum

B. Inhibitory/excitatory imbalance involving GABA and glutamate

C. Dopaminergic deficit in extrastriatal regions

D. All of the above

See the end of this activity for discussion of the best response.

Current Paradigm for Schizophrenia Treatment: D2 Receptor Blockade

Oliver Howes, MRCPsych, PhD

The first antipsychotic drug was discovered almost 70 years ago.[35] In the intervening years, more than 20 different antipsychotics have been developed, and this high number would seem to indicate that patients and providers have many treatment options from which to choose. However, all of these agents are postsynaptic D2 blockers, meaning that treatment options are actually quite limited. With the possible exception of clozapine, all available antipsychotics have the same core mode of action,[36] and, despite variations in non-dopaminergic transmitter interactions, they all have similar benefits and also many of the same drawbacks associated with D2 blockade.

—— View video online ——

Evidence of Antipsychotic D2 Receptor Blockade

In the 1970s, 2 landmark in vitro studies[37,38] were able to demonstrate the link between D2 receptor affinity and antipsychotic clinical potency in vitro. Positron emission tomography (PET) imaging has allowed researchers to observe the effects of antipsychotics on D2 receptors in vivo. In a study of 22 first-episode patients with schizophrenia being treated with haloperidol, Kapur and colleagues[39] used PET imaging and observed that higher D2 receptor occupancy within the first week of treatment predicted greater subsequent clinical response. The finding that symptom reduction can be achieved through blockade of D2 receptors fits with existing knowledge of the neurobiology of schizophrenia. Abnormalities in presynaptic aspects of the dopamine system, in particular the synthesis and release capacity of dopamine, occur in the striatum, which leads to delusions and other positive symptoms. Therefore, blocking the D2 receptors will alleviate these symptoms, but as the D2 receptors are predominantly postsynaptic, these actions are downstream from the dopamine dysfunction seen in the disorder, which is predominantly presynaptic.[25]

This dopamine receptor blocking–based paradigm is the basis of all existing antipsychotic treatment. Numerous placebo-controlled trials conducted over the past 60 years have shown that all available antipsychotics can reduce positive symptoms. Leucht and colleagues[40] conducted a meta-analysis of 167 double-blind, randomized controlled trials of 15 different first- and second-generation antipsychotics and found that twice as many patients improved with antipsychotic treatment compared with those taking placebo.

Limitations of Existing Treatments

Treatment discontinuation. One of the greatest drawbacks of current antipsychotics is that they are associated with high rates of discontinuation. The European First Episode Schizophrenia Trial (EUFEST)[41] found discontinuation rates of between one-third to two-thirds of patients during the first year of treatment. Haloperidol was associated with the highest discontinuation rate (72%) and olanzapine with the lowest (33%). Furthermore, treatment discontinuation is also a problem for patients with chronic schizophrenia. A study[42] conducted as part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) randomly assigned 444 patients who had already discontinued treatment with one second-generation antipsychotic to begin treatment with a different second-generation antipsychotic. This study found that 77% of patients had discontinued treatment with the new antipsychotic over the course of 12 months, highlighting high rates of treatment discontinuation as a major clinical challenge.

Inefficacy. Lack of efficacy is a common reason for treatment discontinuation.[41,42] Although available antipsychotics can alleviate positive symptoms through blocking striatal dopamine D2 receptors, a considerable number of patients fail to show improvement in psychotic symptoms with these agents.[36] Studies have found rates of treatment resistance to range from 23% in first-episode patients[43,44] to 56% in a community sample of chronic patients.[45] The hypothesis was put forth that these patients were not responding to treatment because sufficient D2 receptor blockade was not being achieved, but PET studies have shown comparable dopamine D2 receptor occupancy in both treatment-responsive and treatment-resistant patients, indicating that inadequate D2 receptor blockade does not explain treatment resistance in these patients.[46]

Current antipsychotic treatments are also largely ineffective for the negative and cognitive symptoms of schizophrenia.[47] These symptoms are thought to stem from impaired neural communication caused by disruptions in brain networks, leading to an imbalance of excitatory and inhibitory cortical activity and low dopamine neurotransmission in the cortex and limbic regions. Thus, postsynaptic dopamine D2 receptor blockade would not affect these processes. Moreover, some evidence indicates that the D2 blockade might actually be associated with worsening of negative and cognitive symptoms.[36]

Because more than 20 different antipsychotics are currently available, clinicians appear to have many options to offer patients, but because they are all D2 receptor blockers, clinicians really have very little to offer to patients who do not improve or cannot tolerate their current antipsychotic.

—Dr Howes

For example, healthy volunteers have been found to exhibit negative symptoms and impairments in cognitive functioning after being administered antipsychotic medications.[48,49]

Tolerability. Dopamine D2 receptor occupancy is also related to many of the side effects that often lead to treatment discontinuation. Extrapyramidal side effects, such as akathisia, parkinsonism, and tardive dyskinesia, become more common as dopamine D2 receptor occupancy exceeds about 80%, and hyperprolactinemia increases at D2 receptor occupancy above about 75%.[36] The raised prolactin levels associated with antipsychotic treatment can then lead to sexual side effects.[50]

Available antipsychotics are associated with other troubling side effects that are thought to stem from actions at other receptors.[36] Sedation is most common with clozapine, quetiapine, olanzapine, and chlorpromazine, and these antipsychotics have high affinities for histamine H1 receptors. Anticholinergic effects, such as dry mouth and gastrointestinal disturbance, have been associated with clozapine and olanzapine, which have high affinity for postsynaptic muscarinic receptors.

Perhaps the most problematic side effects of antipsychotic treatment are weight gain and metabolic disturbances. These issues require special attention because they can affect a patient's long-term health. A meta-analysis[51] of over 100 randomized controlled trials, which included more than 25,000 patients, found that even short-term treatment of acute episodes could lead to significant increases in body weight, LDL cholesterol, and glucose levels, any of which can increase a patient's risk of cardiovascular disease in the long-term. These side effects may be in part the indirect result of dopamine D2 receptor blockade as well as the off-target actions at other receptors.[36] Dopamine receptors are involved in reward signaling, and, therefore, blocking D2 receptors may disrupt these reward signals as well as signals of satiety following food consumption and lead to overeating. Overall, one can conclude that the D2 receptor blocking paradigm has many limitations both in terms of efficacy and side effects, highlighting the need for alternative approaches.

New Mechanisms of Action for the Treatment of Schizophrenia

Christoph U. Correll, MD

That only postsynaptic dopamine blockers are available to treat schizophrenia is quite detrimental for this population because of the adverse effects and inefficacy commonly associated with these agents. Improved treatments are needed that are able to control residual positive, negative, and cognitive symptoms while not worsening affective, motor, and cardiometabolic domains. Currently, 4 medications have shown promise for the treatment of symptoms in schizophrenia without blocking the postsynaptic dopamine receptor (**Figure 6**).[1,31,52,54–56]

—— View video online ——

Ulotaront

As discussed previously in the overview of the article by Koblan et al,[1] ulotaront is a TAAR1 and 5-HT1A agonist, and although the specific mechanism of action has not been fully elucidated, agonism at these 2 receptors contributes to its efficacy.[2] Two review articles[31,52] note that when the TAAR1 receptor is stimulated, several important events occur. These include a dimerization of the TAAR1 receptor with the postsynaptic D2 receptor, which leads to internalization of the D2 receptor (see part A of **Figure 6**). Therefore, less D2 receptor occupancy is possible without actually blocking the D2 receptor. Furthermore, presynaptic firing of dopamine is also reduced and has been shown to reduce excess striatal dopamine synthesis in a model of the pathophysiology of schizophrenia.[53] Thus, ulotaront might represent the first presynaptic treatment for schizophrenia. This development is noteworthy because this agent would be targeting one of the actual mechanisms underlying the pathophysiology of schizophrenia—the overproduction of dopamine—rather than a dysfunction of postsynaptic dopamine receptors that has not been clearly proven. Additionally, TAAR1 receptors also exist in the periphery and regulate appetite, reduce fasting glucose in the liver, increase insulin production, and delay gastric emptying, all of which contribute to improved glucose levels and metabolism.[31]

In the previously discussed phase 2 study published in *The New England Journal of Medicine*,[1] ulotaront treatment for 4 weeks at doses of 50 or 75 mg/d was associated with significantly greater reductions in PANSS total scores, CGI-S scores, and all PANSS subscale scores compared with placebo. Also, although patients were not selected for having particularly high negative or depressive symptoms, those receiving ulotaront treatment also showed significantly more improvement on Brief Negative Symptom Scale and Montgomery-Asberg Depression Rating Scale scores compared with those receiving placebo. Few adverse effects emerged, with

Figure 6. Novel Therapeutic Targets Being Investigated for Schizophrenia[a]

[a]Currently available drugs for schizophrenia work by blocking postsynaptic dopamine D2 receptors throughout the brain. Some have partial D2 agonism. Four novel antipsychotics are in development for schizophrenia that have demonstrated varying degrees of antipsychotic efficacy without postsynaptic D2 receptor blockade.

A. Ulotaront (SEP-363856) is a TAAR1 agonist with demonstrated antipsychotic efficacy for acute schizophrenia in one phase 2 study.[1] Although the specific mechanism of action is still unclarified, previous studies[31,52] indicate that when intracellular TAAR1 is activated presynaptically, it creates a dimer with the postsynaptic dopamine D2 receptor. This heterodimer is then internalized and no longer available for dopamine occupancy. Additionally, TAAR1 agonism also reduces the firing of dopamine neurons to reduce presynaptic dopamine dysfunction.[1]

B. KarXT (xanomeline+trospium) and CVL-231 both act on presynaptic muscarinic autoreceptors, which indirectly regulate dopamine release via reducing acetylcholine release. KarXT is an agonist of M1 and M4 receptors with demonstrated antipsychotic efficacy for acute schizophrenia in one phase 2 study.[54] CVL-231 is an M4 positive allosteric modulator with a positive phase 1b study in patients with acute exacerbation of schizophrenia.[55]

C. Pimavanserin, approved for Parkinson's psychosis, is a potent inverse agonist and antagonist at 5-HT2A serotonin receptors and has less potent action at 5-HT2C receptors. 5-HT2A inverse agonism and strong antagonism are thought to indirectly increase dopamine output in the mesocortical and the sensorimotor nigrostriatal pathway 2 (see Figure 5). Pimavanserin has shown efficacy in one phase 2 study for predominant negative symptoms in schizophrenia.[56]

the most common being somnolence, agitation, and nausea, which ranged from 5%–7% with ulotaront and 3%–5% for placebo. Notably, weight gain was minimal at 0.3 kg in patients receiving ulotaront compared with –0.1 kg in patients receiving placebo. No appreciable effects on metabolic parameters were detected.

In the open-label extension study,[3] 157 (81.3%) of the 193 4-week completers continued into the open-label extension study, of whom 66.9% completed the 26-week study. In this 26-week study, ulotaront flexibly dosed at 25–75 mg continued to be associated with minimal changes in body weight (–0.3 ± 3.7 kg), lipid, glucose, and prolactin parameters. Movement disorder scales indicated no extrapyramidal effects. Moreover, continued improvements in change from open-label baseline in the PANSS total score of –22.6 were observed.

Xanomeline

Xanomeline is a muscarinic cholinergic receptor agonist that preferentially stimulates M1 and M4 receptors (see part B of **Figure 6**).[54] The M4 receptor is mostly distributed in the brain, and stimulation of the M4 autoreceptor downstream reduces acetylcholine release at the interneuronal level, reducing dopamine transmission. Therefore, there is decreased dopamine transmission and firing without blockade of the postsynaptic dopamine receptor. In early trials of xanomeline for the treatment of Alzheimer's disease and schizophrenia, patients experienced cholinergic side effects serious enough to halt investigation despite promising improvements in psychotic symptoms. When clinical development resumed, xanomeline was combined with trospium, a non–centrally active anticholinergic medication. This combination led to a clinically relevant reduction in the incidence of anticholinergic side effects during treatment with xanomeline.

In a phase 2B study by Brannan and colleagues,[54] 182 patients with schizophrenia were randomly assigned in a 1:1 ratio to receive either xanomeline-trospium or placebo for 5 weeks. Xanomeline was started at 50 mg twice

a day combined with 20 mg of trospium and increased to 125 mg of xanomeline and 30 mg of trospium twice a day. Dosage could be reduced to 100 mg of xanomeline and 20 mg of trospium if tolerability issues arose. After 5 weeks, patients receiving xanomeline-trospium showed a significantly greater reduction in scores on both the PANSS total and subscale scores ($P < .001$). Patients in the active treatment group experienced more side effects than those in the placebo group, with the most common being constipation (17% vs 3% with placebo), nausea (17% vs 12% with placebo), dry mouth (9% vs 1% with placebo), dyspepsia (9% vs 4% with placebo), and vomiting (9% vs 4% with placebo). Despite these adverse events, very few people discontinued treatment. In terms of weight gain, patients in the xanomeline-trospium group gained an average of 1.5 kg compared with an increase of 1.1 kg in the placebo group. No appreciable changes in extrapyramidal side effects, akathisia, and metabolic parameters were observed.

CVL-231

CVL-231 is an M4 positive allosteric modulator that is thought to prevent acetylcholine release by activating M4 autoreceptors (see part B of **Figure 6**).[55] Without acetylcholine, dopamine output decreases, potentially reducing psychotic symptoms. CVL-231 was investigated in a phase 1B trial that was mainly designed to be a dose-finding and pharmacokinetic study. The 81 enrolled patients were randomized at 27 patients each to either placebo, 30 mg of CVL-231 once per day, or 20 mg of CVL-231 twice a day. Although this study is limited by its small sample size, at the end of the 6-week study, both doses of CVL-231 were associated with significantly greater reductions vs placebo in total PANSS score (CVL-231 30 mg qd: $P = .023$; CVL-231 20 mg bid: $P = .047$) and PANSS negative symptom scale scores (CVL-231 30 mg qd: $P = .009$; CVL-231 20 mg bid: $P = .002$).[57] In terms of positive symptoms, only the 30-mg, once-daily dose was significantly superior to placebo ($P = .016$). Few side effects emerged, with the most common being

Seventy years after the discovery of the first treatment for psychosis, 4 new treatments, each with a different mechanism of action, are being investigated for schizophrenia and show promise for greater efficacy and tolerability than currently available antipsychotics.

—Dr Correll

nausea at 7% for both doses of CVL-231 compared to 4% with placebo. All other side effects occurred at 2% or less with CVL-231.

Pimavanserin

Pimavanserin, which is approved for the treatment of Parkinson's psychosis, is currently being studied as an adjunctive treatment to antipsychotics to address negative and residual positive symptoms.[56] Pimavanserin is a potent inverse agonist and antagonist at 5-HT2A serotonin receptors and has less potent action at 5-HT2C receptors (see part C of **Figure 6**). This agent has no direct action at dopamine, adrenergic, histamine, serotonin, or cholinergic receptors.[58]

The efficacy of pimavanserin 20 mg and 34 mg for treating negative symptoms was evaluated in a 6-month, double-blind, placebo-controlled phase 2B study called the ADVANCE trial.[56] After 26 weeks, the patients in the pimavanserin group showed significantly more improvement on the Negative Symptom Assessment-16 (NSA) compared with those receiving placebo, but with only a modest effect size of 0.2. However, at the 34-mg dose approved for Parkinson's psychosis, the effect size was higher, at 0.34. Interestingly, pimavanserin showed no significant benefit over placebo on the PANSS-Negative symptoms score, the NSA-16 Negative Symptoms subscale score, or the CGI Schizophrenia-Severity scale. Side effects were minimal, with the most frequent being headache (6.5% vs 5% with placebo) and somnolence (5.5% vs 5% with placebo).

A second double-blind, placebo-controlled study called the ENHANCE trial investigated pimavanserin as an adjunctive treatment for residual

positive symptoms.[56] After 6 weeks of treatment, those receiving adjunctive pimavanserin failed to show significantly greater improvement in either PANSS total or positive symptom scale scores compared with those receiving placebo. However, in a preplanned subgroup analysis of the 80% of the sample that was investigated at non-US sites, pimavanserin did separate from placebo for positive symptoms; in the entire sample, pimavanserin separated from placebo regarding negative symptoms. Pimavanserin was well tolerated in both the ADVANCE and ENHANCE trials. The occurrence of side effects was comparable in the pimavanserin and placebo groups, with the most commonly reported side effects being headache, somnolence, and insomnia (pimavanserin: 5%–7%, placebo: 3%–9%).

Conclusion

In summary, novel mechanisms of action are sorely needed in the treatment of schizophrenia. Previously, lack of knowledge about the pathophysiology of schizophrenia made it difficult to develop and evaluate effective novel mechanisms of action. Advances in imaging technology and drug design have created the potential for new treatments that do not directly block postsynaptic dopamine receptors. This may lead to treatments that not only are effective for patients who do not respond to currently available antipsychotics, but also do not lead to the side effects that stem from dopamine receptor blockade, including parkinsonism, akathisia, prolactin elevation, and weight gain, among others.

Encouraging phase 2 results exist for the TAAR1 agonist, ulotaront, indicating efficacy for total psychotic symptoms with improvement on all PANSS subscale scores. Phase 2B results are available for the M1/M4 agonist, xanomeline, coupled with the peripheral anticholinergic, trospium, with efficacy for total psychotic symptoms and improved subscale scores on the PANSS. Positive phase 1B trial results show efficacy of the M4 positive allosteric modulator, CVL-231, for total symptoms and negative symptoms, and the adjunctive use of the serotonin 2A inverse agonist/antagonist, pimavanserin, for the improvement of negative symptoms. These phase 1B and phase 2B trial results are promising and exciting but must be confirmed with larger phase 3 trials before regulatory approval can be sought.

Any of these mechanisms of action would represent a significant advance in the treatment of schizophrenia. Great hope exists that at least one of these agents with novel mechanisms will be successful in a phase 3 trial so that patients and families can benefit from this new kind of treatment.

Test Your Knowledge 3

What is *not* a mechanism of action of the 4 promising medications for schizophrenia that each have had one recent positive placebo-controlled trial in patients with schizophrenia?

A. 5-HT serotonin 2A inverse agonism/antagonism

B. TAAR1 agonism

C. M1/M4 muscarinic agonism

D. NMDA glutamatergic receptor agonism

See the end of this activity for discussion of the best response.

Clinical Points

- Schizophrenia symptoms typically emerge in late adolescence or early adulthood, but brain changes underlying the symptoms begin during gestation and continue through the lifespan. Many symptoms are thought to involve dysfunction in neural networks that are essential for processing information and controlling behavior.

- Although more than 20 antipsychotics are available, they are all postsynaptic D2 blockers and share similar benefits and limitations. Discontinuation of antipsychotics may stem from lack of efficacy, intolerable side effects, or worsening of cognitive or negative symptoms.

- Four medications, ulotaront, xanomeline+trospium, CVL-231, and pimavanserin, have shown promise for treating symptoms in schizophrenia without blocking the postsynaptic dopamine receptor.

Discussion of Test Your Knowledge Questions

Question 1: **Preferred response is D.**
Schizophrenia may involve dysfunction in multiple transmitter systems leading to symptoms along most functional domains.

Question 2: **Preferred response is C.**
The majority of patients with schizophrenia discontinue treatment within months of starting it due to inefficacy or side effects, highlighting the need for better tolerated and more effective alternatives.

Question 3: **Preferred response is D.**
Pimavanserin, under investigation as an adjunctive agent for predominant negative symptoms in schizophrenia, is a 5-HT serotonin 2A inverse agonist. Ulotaront is a TAAR1 and 5-HT1A agonist with a positive phase 2 result for total symptoms of schizophrenia. Xanomeline, which together with the peripheral anticholinergic trospium forms KarXT, is an M1/M4 muscarinic agonist currently undergoing testing as monotherapy and adjunctive therapy for total symptoms of schizophrenia. While glutamatergic NMDA receptor agonists have been investigated for negative symptoms and cognition in schizophrenia in the past with mixed results, there has been no recent positive trial for this mechanism of action.

REFERENCES

1. Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. *N Engl J Med*. 2020;382(16):1497–1506.
2. Dedic N, Jones PG, Hopkins SC, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. *J Pharmacol Exp Ther*. 2019;371(1):1–14.
3. Correll CU, Koblan KS, Hopkins SC, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. *NPJ Schizophr*. 2021;7(1):63.
4. Lieberman JA, Jarskog LF, Malaspina D. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. *J Clin Psychiatry*. 2006;67(6):983–990.
5. Insel TR. Rethinking schizophrenia. *Nature*. 2010;468(7321):187–193.
6. Ellison-Wright I, Glahn DC, Laird AR, et al. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. *Am J Psychiatry*. 2008;165(8):1015–1023.
7. Lewis DA, Lieberman JA. Catching up on

schizophrenia: natural history and neurobiology. *Neuron*. 2000;28(2):325–334.

8. Lener MS, Wong E, Tang CY, et al. White matter abnormalities in schizophrenia and schizotypal personality disorder. *Schizophr Bull*. 2015;41(1):300–310.

9. Schobel SA, Lewandowski NM, Corcoran CM, et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. *Arch Gen Psychiatry*. 2009;66(9):938–946.

10. Horga G, Schatz KC, Abi-Dargham A, et al. Deficits in predictive coding underlie hallucinations in schizophrenia. *J Neurosci*. 2014;34(24):8072–8082.

11. Yeo BTT, Krienen FM, Sepulcre J, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. *J Neurophysiol*. 2011;106(3):1125–1165.

12. Horga G, Cassidy CM, Xu X, et al. Dopamine-related disruption of functional topography of striatal connections in unmedicated patients with schizophrenia. *JAMA Psychiatry*. 2016;73(8):862–870.

13. Surmeier DJ, Ding J, Day M, et al. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. *Trends Neurosci*. 2007;30(5):228–235.

14. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III–the final common pathway. *Schizophr Bull*. 2009;35(3):549–562.

15. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. *Arch Gen Psychiatry*. 2010;67(3):231–239.

16. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. *Arch Gen Psychiatry*. 2009;66(1):13–20.

17. Radua J, Schmidt A, Borgwardt S, et al. Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis. *JAMA Psychiatry*. 2015;72(12):1243–1251.

18. Schultz W. Dopamine reward prediction error coding. *Dialogues Clin Neurosci*. 2016;18(1):23–32.

19. Katthagen T, Kaminski J, Heinz A, et al. Striatal dopamine and reward prediction error signaling in unmedicated schizophrenia patients. *Schizophr Bull*. 2020;46(6):1535–1546.

20. Arias-Carrión O, Stamelou M, Murillo-Rodríguez E, et al. Dopaminergic reward system: a short integrative review. *Int Arch Med*. 2010;3(1):24.

21. O'Donnell P. Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models. *Schizophr Bull*. 2011;37(3):484–492.

22. Slifstein M, van de Giessen E, Van Snellenberg J, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. *JAMA Psychiatry*. 2015;72(4):316–324.

23. Cassidy CM, Van Snellenberg JX, Benavides C, et al. Dynamic connectivity between brain networks supports working memory: relationships to dopamine release and schizophrenia. *J Neurosci*. 2016;36(15):4377–4388.

24. Lobb CJ, Wilson CJ, Paladini CA. A dynamic role for GABA receptors on the firing pattern of midbrain dopaminergic neurons. *J Neurophysiol*. 2010;104(1):403–413.

25. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. *World Psychiatry*. 2020;19(1):15–33.

26. Driesen NR, McCarthy G, Bhagwagar Z, et al. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. *Mol Psychiatry*. 2013;18(11):1199–1204.

27. Marsman A, van den Heuvel MP, Klomp DWJ, et al. Glutamate in schizophrenia: a focused review and meta-analysis of ^{1}H-MRS studies. *Schizophr Bull*. 2013;39(1):120–129.

28. Raedler TJ, Bymaster FP, Tandon R, et al. Towards a muscarinic hypothesis of schizophrenia. *Mol Psychiatry*. 2007;12(3):232–246.

29. Scarr E, Gibbons AS, Neo J, et al. Cholinergic connectivity: it's implications for psychiatric disorders. *Front Cell Neurosci*. 2013;7:55.

30. Rutigliano G, Accorroni A, Zucchi R. The case for TAAR1 as a modulator of central nervous system function. *Front Pharmacol*. 2018;8:987.

31. Berry MD, Gainetdinov RR, Hoener MC, et al. Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. *Pharmacol Ther*. 2017;180:161–180.

32. Espinoza S, Salahpour A, Masri B, et al. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. *Mol Pharmacol*. 2011;80(3):416–425.

33. Dedic N, Dworak H, Zeni C, et al. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. *Int J Mol Sci*. 2021;22(24):13185.

34. Rutigliano G, Zucchi R. Molecular variants in human trace amine-associated receptors and their implications in mental and metabolic disorders. *Cell Mol Neurobiol*. 2020;40(2):239–255.

35. López-Muñoz F, Alamo C, Cuenca E, et al. History of the discovery and clinical introduction of chlorpromazine. *Ann Clin Psychiatry*. 2005;17(3):113–135.

36. Kaar SJ, Natesan S, McCutcheon R, et al. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. *Neuropharmacology*. 2020;172:107704.

37. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. *Science*. 1976;192(4238):481–483.

38. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. *Nature*. 1976;261(5562):717–719.

39. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. *Am J Psychiatry*. 2000;157(4):514–520.

40. Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. *Am J Psychiatry*. 2017;174(10):927–942.

41. Kahn RS, Fleischhacker WW, Boter H, et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet*. 2008;371(9618):1085–1097.

42. Stroup TS, Lieberman JA, McEvoy JP, et al; CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry*. 2006;163(4):611–622.

43. Lally J, Ajnakina O, Di Forti M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. *Psychol Med*. 2016;46(15):3231–3240.

44. Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. *Psychol Med*. 2017;47(11):1981–1989.

45. Beck K, McCutcheon R, Stephenson L, et al. Prevalence of treatment-resistant psychoses in the community: a naturalistic study. *J Psychopharmacol*. 2019;33(10):1248–1253.

46. Leung CCY, Gadelrab R, Ntephe CU, et al. Clinical course, neurobiology and therapeutic approaches to treatment resistant schizophrenia. toward an integrated view. *Front Psychiatry*. 2019;10:601.

47. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-an overview. *JAMA Psychiatry*. 2020;77(2):201–210.

48. Artaloytia JF, Arango C, Lahti A, et al. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. *Am J Psychiatry*. 2006;163(3):488–493.

49. Kim E, Howes OD, Turkheimer FE, et al. The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: a dual [(11)C]raclopride and [(18)F]FDG imaging study with aripiprazole. *Psychopharmacology (Berl)*. 2013;227(2):221–229.

50. Knegtering H, van den Bosch R, Castelein S, et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? *Psychoneuroendocrinology*. 2008;33(6):711–717.

51. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry*. 2020;7(1):64–77.

52. Miller GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. *J Neurochem*. 2011;116(2):164–176.

53. Kokkinou M, Irvine EE, Bonsall DR, et al. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. *Mol Psychiatry*. 2021;26(6):2562–2576.

54. Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. *N Engl J Med*. 2021;384(8):717–726.

55. Transforming the Possible in Neuroscience: Topline Data for Phase 1b Trial of CVL-231 in Schizophrenia. Cerevel website. https://investors.cerevel.com/static-files/31d256be-15f7-4340-8af3-7cdd058308fe. Published June 2021.

56. Davis J, Zamora D, Horowitz M, et al. Evaluating pimavanserin as a treatment for psychiatric disorders: a pharmacological property in search of an indication. *Expert Opin Pharmacother*. 2021;22(13):1651–1660.

57. Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia. Cerevel website. https://investors.cerevel.com/news-releases/news-release-details/cerevel-therapeutics-announces-positive-topline-results-cvl-231/. Published June 29, 2021. Accessed December 29, 2021.

58. Hunter NS, Anderson KC, Cox A. Pimavanserin. *Drugs Today (Barc)*. 2015;51(11):645–652.

TAAR1 EDUCATIONAL RESOURCE VIDEO

See a short video explaining how trace amine–associated receptor 1 (TAAR1) affects neurotransmitters in the brain.

This video is a publicly available educational resource provided by Sunovion Pharmaceuticals Inc. It was produced prior to and independent of this InfoPack.

Scan this QR code to access